Bone density testing: Science, the media, and patient care

Current Osteoporosis Reports

Volumn 12, Issue 2, 2014, Pages 227-229

  Rothman, Micol S ^a   Miller, Paul D ^a,b   Lewiecki, E Michael ^c,d   Bilezikian, John P ^e  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Health Sciences Center and Colorado Center for Bone Research   (United States)

^c Osteoporosis Center   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

DXA; Media; Monitoring; Osteoporosis

Indexed keywords

ACCURACY; BONE DENSITY; BONE MASS; CLINICAL DECISION MAKING; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; NOTE; OSTEOPOROSIS; PATIENT CARE; PATIENT SAFETY; PRACTICE GUIDELINE; PREDICTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; MASS MEDIUM; MASS SCREENING; PHOTON ABSORPTIOMETRY; RADIOGRAPHY; UTILIZATION;

ABSORPTIOMETRY, PHOTON; BONE DENSITY; HUMANS; MASS MEDIA; MASS SCREENING; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC;

EID: 84904183466     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-014-0203-6     Document Type: Note

References (14)

1. Gourlay ML et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366(3):225-33.
2. Lewiecki EM et al. More bone density testing is needed, not less. J Bone Miner Res. 2012;27(4):739-42.
3. Berry SD et al. Repeat bone mineral density screening and prediction of hip and major osteoporotic fracture. JAMA. 2013;310(12):1256-62.
4. Combs BP et al. "Due" for a scan: examining the utility of monitoring densitometry. JAMA Int Med. 2013;173(21):2007-9.
5. Sebba AI. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment. Clin Ther. 2008;30(3):443-52. (Pubitemid 351483927)
6. Watts NB et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16 Suppl 3:1-37.
7. Jacques RM et al. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(8):1627-34.
8. Austin M et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2012;27(3):687-93.
9. Foundation NO. Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation. 2013.
10. King AB, Fiorentino DM. Medicare payment cuts for osteoporosis testing reduced use despite tests' benefit in reducing fractures. Health Aff. 2011;30(12):2362-70.
11. Reid IR, Gamble GD. Intervals between bone density testing. J Bone Miner Res. 2014;29(2):389-91.
12. Dell R et al. Osteoporosis disease management: the role of the orthopaedic surgeon. J Bone Joint Surg Am. 2008;90 Suppl 4:188-94.
13. Newman ED et al. Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int. 2003;14(2):146-51. (Pubitemid 40824231)
14. Watts NB, et al. The clinical value of monitoring bone density in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res. 2009;24: [Epub].